Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 7/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128453 | 0.89 | CYP3A4 (0.67) | CYP3A4CYP2C9GPR119 | |
| SCHEMBL9007096 | 0.88 | CYP3A4 (0.52) | CYP3A4CYP2C9PDE9ABTKGPR119 | |
| SCHEMBL4355956 | 0.86 | CYP3A4 (0.57) | CYP3A4CYP2C9PDE9ABTKGPR119 | |
| SCHEMBL4354583 | 0.84 | CYP3A4 (0.60) | CYP3A4CYP2C9BTKFLT3 | |
| SCHEMBL4459446 | 0.84 | CYP3A4 (0.62) | CYP3A4CYP2C9BTKGPR119 | |
| SCHEMBL4350405 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9BTKFLT3 | |
| SCHEMBL4357229 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP2C9PDE9AGPR119 | |
| SCHEMBL4359029 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP2C9PDE9AGPR119JAK2 | |
| SCHEMBL4368642 | 0.83 | GPR119 (0.49) | CYP3A4CYP2C9PDE9AGPR119FLT3 | |
| SCHEMBL4358056 | 0.82 | CYP3A4 (0.49) | CYP3A4CYP2C9PDE9AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885CYP2C9 917/4885PDE9A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.